| Name | Title | Contact Details |
|---|
Action Revenue Recovery is a Monroe, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bruce Leeb and Company is a Fair Lawn, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Parkland is a diverse community of 30,000, and the City provides a variety of services for these citizens. Learn more about what Parkland has to offer you and your family! Parkland is a tranquil city nestled in a serene, wooded environment in Northwest...
The Franciscan Alliance healthcare ministry began in Lafayette` Ind.` in 1875. Today` Franciscan Alliance is one of the largest Catholic health care systems in the Midwest with 14 hospital campuses in Indiana and Illinois` approximately 20`000 employees and a number of nationally recognized Centers of Health Care Excellence. Hospitals include: Franciscan Health Crown Point; Franciscan Health Michigan City; Franciscan Health Crawfordsville; Franciscan Health Lafayette East; Franciscan Health Lafayette Central; Franciscan Health Indianapolis; Franciscan Health Carmel; Franciscan Health Rensselaer; Franciscan Health Mooresville; Franciscan Health Chicago Heights` Ill.; Franciscan Health-Olympia Fields` Ill.; Franciscan Health Hammond; Franciscan Health Dyer; and Franciscan Health Munster. For more information` visit FranciscanHealth.org. With more than 850 primary and specialty care providers at over 260 locations in Indiana and Illinois` Franciscan Physician Network is one of the largest and most respected multi-specialty physician networks in the Midwest providing convenient` comprehensive care.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.